Trial Profile
A Phase I Trial of Ipilimumab (Immunotherapy) and MGN1703 (TLR Agonist) in Patients With Advanced Solid Malignancies
Status:
Active, no longer recruiting
Phase of Trial:
Phase I
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Lefitolimod (Primary) ; Lefitolimod (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 20 Oct 2023 Planned End Date changed from 31 May 2024 to 31 May 2025.
- 20 Oct 2023 Planned primary completion date changed from 31 May 2023 to 31 May 2025.
- 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology